Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-06-18

The role of Tumour suppressor of lung cancer 1 (TSLC1) signalling in lung repair and cancer-associated epithelial-mesenchymal transitions (EMTs)

Ziel

Chronic lung diseases including COPD and cancer account for more than 10% of deaths in European countries and lung cancer remains the most common and most lethal cancer type worldwide. Lung cancer mortality rates have also remained constant for over 40 years, largely due to late stage diagnosis and frequent metastases. Despite these trends the signalling pathways regulating lung cancers remain largely unexplored. Although loss of Tumour Suppressor of Lung Cancer 1 (TSLC1) is implicated in lung cancer metastases its normal lung functions remain entirely unknown. Recently, I determined that the TSLC1 signalling pathway regulates cell proliferation, motility, skin repair, and cancer severity by inhibiting stem cell EMTs. This proposal will determine how TSLC1 regulates lung EMTs to influence repair and disease outcomes. I will correlate TSLC1 expression with EMTs in repairing and diseased lungs, investigate how lung TSLC1
signalling influences repair and disease outcomes using transgenic and knockout mice, and identify mechanisms through which TSLC1 modulates lung phenotypes using in vitro overexpression and knockdown studies. This research will elucidate TSLC1 signalling pathway functions in lungs and should suggest new therapeutic opportunities for human lung disease.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

ERC-2010-StG_20091118
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

ERC-SG - ERC Starting Grant

Gastgebende Einrichtung

UNIVERSITY COLLEGE LONDON
EU-Beitrag
€ 1 489 715,00
Gesamtkosten
Keine Daten

Begünstigte (1)